On 16 March 2015, the Competition Commission of Singapore (“CCS”) announced that it had taken a provisional decision to block the proposed acquisition of RadLink-Asia Pte Limited (“RadLink”), a wholly owned subsidiary of Fortis Healthcare Singapore Pte. Limited (“Fortis Singapore”) by Medi-Rad Associates Ltd (“Medi-Rad”), a wholly-owned subsidiary of Parkway Holdings Ltd (“Parkway”) (Parkway and Fortis Singapore collectively, the “Parties”) (the “Proposed Transaction”). The provisional decision by the CCS to block the Proposed Transaction represents the second-ever provisional decision by the CCS to block a merger on the basis that it could result in a substantial lessening of
Share on
|
|
The Singaporean Competition Authority takes a provisional decision to block a proposed acquisition in the radiology and imaging services sector (RadLink-Asia / Fortis Singapore)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
